A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease

Respiratory Research

Table 2 Rate of FVC decline between ILD clusters

ILD subtype	Cluster	Number of patients	Predominant cluster features (sex, comorbidities)	Annual change in FVC (%-predicted)	95% CI
IPF	1	59	Female, none	− 8.1	− 13.6, − 2.7
	2	136	Male, none	− 8.8	− 11.3, − 6.3
	3	79	Male, GERD or MI	− 9.0	− 11.8, − 6.1
	4	56	Male, OSA	− 11.9	− 15.3, − 8.5
CTD-ILD	1	237	Female, any tumor or none	− 0.9	− 2.9, 1.1
	2	157	Female or male, cardiovascular risk factors*	− 1.4	− 3.2, 0.3
	3	136	Male, none	0.4	− 1.2, 1.9
	4	142	Female, GERD	− 0.2	− 1.5, 1.0
Fibrotic HP	1	62	Male, none	− 0.04	− 8.9, 8.8
Fibrotic HP	2	73	Female, GERD or OSA	1.0	− 5.7, 7.8
Unclassifiable	1	103	Male, Diabetes or OSA	1.1	− 3.3, 5.3
	2	189	Female or male, none	− 1.4	− 3.9, 1.1
	3	51	Female or male, GERD	− 0.2	− 3.1, 2.6

In IPF, cluster 4 had a significantly greater rate of FVC decline compared to cluster 1 (p = 0.03). There were no significant differences between the other clusters
CI confidence interval, FVC forced vital capacity, GERD gastroesophageal reflux disease, MI myocardial infarction, OSA obstructive sleep apnea
*Cardiovascular risk factors include myocardial infarction, congestive heart failure, cerebrovascular disease, diabetes, and obstructive sleep apnea

ISSN: 1465-993X